The hallmarks of aging framework (Lopez-Otin et al., 2013, *Cell*) identifies nine core biological processes that underlie aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Longevity research compounds are evaluated on how many of these hallmarks they address and with what mechanistic specificity.

Mitochondrial dysfunction is increasingly recognized as a central driver of the aging phenotype — mitochondria produce the energy currency (ATP) and reactive oxygen species (ROS) that affect nearly every other hallmark. This is why several of the most compelling longevity compounds (SS-31, MOTS-c, NAD+) target mitochondrial biology specifically.

Peptide-based longevity research has advantages over small molecules in some respects: peptides can be designed to target specific organelle compartments (SS-31 accumulates in the inner mitochondrial membrane), act as signaling molecules that activate endogenous longevity pathways (MOTS-c activates AMPK), or modulate gene expression programs at scale (GHK-Cu).

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme central to cellular energy metabolism and a key substrate for the sirtuin family of longevity proteins (SIRT1-7). NAD+ levels decline with age in most tissues — this decline is mechanistically linked to reduced sirtuin activity, impaired mitochondrial function, and increased cellular senescence.

Research by David Sinclair's laboratory at Harvard and others has established that restoring NAD+ levels extends lifespan in multiple model organisms and improves age-related phenotypes in mice, including muscle function, cognitive performance, and cardiovascular health. Published mouse studies using NAD+ precursors (NMN and NR) show that even late-in-life supplementation reverses some age-related vascular and metabolic deterioration.

NAD+'s longevity mechanisms include: sirtuin activation (SIRT1 deacetylates and activates PGC-1α, a master regulator of mitochondrial biogenesis), PARP inhibition competition (NAD+ is consumed by PARPs in DNA repair; age-related DNA damage creates a "PARP trap" that depletes NAD+, which NAD+ repletion can break), and CD38 pathway effects (CD38, an NAD+ hydrolase that increases with aging, is implicated in the age-related NAD+ decline).

For research purposes, NAD+ itself (as distinct from NMN/NR precursors) is used in cell culture and some animal models to directly test NAD+-dependent mechanisms.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondria-encoded peptide — one of the first mitochondrial microproteins (mitokines) to be characterized as a signaling molecule. It is encoded within the 12S rRNA gene of the mitochondrial genome and was first described by the Chang lab at USC in 2015.

MOTS-c is exceptional because it translocates from mitochondria to the nucleus under metabolic stress conditions, where it activates AMPK and regulates nuclear gene expression programs related to metabolism, stress resistance, and inflammation. This mitochondria-to-nucleus signaling is a novel form of inter-organelle communication that has attracted substantial interest in aging biology.

Published MOTS-c research (Lee et al., 2015, *Cell Metabolism*) demonstrated that MOTS-c administration improved insulin sensitivity and reduced obesity in high-fat diet mouse models. Subsequent research showed MOTS-c levels decline with age in humans and mice, and that MOTS-c administration in aged mice extended physical performance and reduced age-associated metabolic dysfunction. A 2021 paper in *Nature Communications* from the same group demonstrated that MOTS-c injection extended lifespan in aged mice when started late in life — one of only a handful of interventions showing lifespan extension with late-life initiation.

MOTS-c is also studied for its anti-inflammatory properties: it reduces circulating inflammatory cytokines and activates Nrf2 antioxidant responses, addressing multiple aging hallmarks simultaneously.

SS-31 (Szeto-Schiller 31, also known as Elamipretide) is a mitochondria-targeted tetrapeptide developed by Hazel Szeto at Cornell/Weill Cornell. Its unique property is selective accumulation in the inner mitochondrial membrane (IMM) through electrostatic interaction with cardiolipin — a phospholipid essential for the organization of respiratory chain supercomplexes.

Cardiolipin content and composition decline with aging and in many disease states, disrupting the structural organization of the electron transport chain (ETC) and reducing mitochondrial membrane potential. SS-31 stabilizes cardiolipin in the IMM, restoring ETC supercomplex organization, reducing electron leak (and thus ROS production), and improving ATP synthesis efficiency.

The published SS-31 research record is substantial and crosses multiple aging phenotypes. A landmark study by Whitson et al. (2020, *Aging Cell*) demonstrated that SS-31 treatment in aged mice reversed age-related cardiac dysfunction — improving cardiac output to levels indistinguishable from young animals — through mitochondrial cristae remodeling and ETC restoration. Similar results have been published in skeletal muscle, kidney, and brain models.

SS-31's mechanism makes it particularly valuable for research into mitochondrial-dependent aging phenotypes — the tissue aging processes (cardiac, renal, skeletal muscle) where declining mitochondrial function is a primary driver rather than a secondary consequence. It has completed Phase 2 clinical trials in Barth syndrome (a genetic cardiolipin disorder), providing translational data in a human mitochondrial disease context.

GHK-Cu in the longevity context is studied primarily for its genome-wide gene regulation effects — Pickart & Margolina's 2018 bioinformatics analysis identified over 4,000 human genes modulated by GHK-Cu, with particular enrichment in gene sets for DNA repair, proteasome function, mitochondrial biogenesis, and anti-senescence pathways. This gene expression data positions GHK-Cu as potentially addressing multiple aging hallmarks simultaneously.

Published skin aging research — where GHK-Cu has the most developed evidence base — shows that it reverses some gene expression changes associated with aging skin. A 2009 microarray study found that GHK-Cu treatment of aging human fibroblasts reversed approximately 70% of the gene expression changes characteristic of aging, restoring a more youthful expression profile.

For systemic longevity research, GHK-Cu's most relevant documented effects include: upregulation of proteasome subunits (addressing proteostasis hallmark), activation of DNA repair enzymes (OGG1, ERCC1), anti-inflammatory gene expression (reduced IL-1β, TNF-α, IL-6), and upregulation of collagen and extracellular matrix remodeling genes.

GHK-Cu levels in human plasma decline significantly with age — from approximately 200 ng/mL at age 20 to near-undetectable levels by age 60 — suggesting it functions as an endogenous repair signal whose decline may contribute to age-related tissue deterioration.

Published longevity research increasingly examines combinations of complementary compounds rather than single agents, reflecting the multi-hallmark nature of aging. For researchers building preclinical longevity protocols, the four compounds in this article offer distinct mechanistic contributions:

NAD+ addresses sirtuin activity and energy metabolism — upstream metabolic regulators of multiple longevity pathways.

MOTS-c provides AMPK activation and mitokine signaling — the nuclear gene expression response to mitochondrial metabolic status.

SS-31 directly targets structural mitochondrial dysfunction at the cardiolipin/cristae level — the bioenergetic core of cellular aging.

GHK-Cu contributes broad genomic remodeling toward a pro-repair, anti-inflammatory, anti-senescent gene expression pattern.

These mechanisms are largely non-overlapping, suggesting that combination protocols may be additive or synergistic. Published mouse combination studies are still limited, but the mechanistic rationale for multi-compound approaches in longevity research is strong.

All compounds described are research-use-only materials. Longevity research in humans requires clinical trial frameworks and regulatory oversight beyond the scope of preclinical peptide research.